iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.

iCAD to Report Second Quarter 2021 Financial Results on Thursday, August 5

iCAD's third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations iCAD's third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations

iCAD's ProFound AI for Digital Breast Tomosynthesis Version 3.0 Receives CE Mark Approval

Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide

iCAD Signs Global Distribution Agreement with Sectra

iCAD, Inc. is a global medical technology company developing cancer detection and therapy solutions across their two respective segments. ICAD operates across two segments: Detection and Therapy offering various solutions including computer-aided detection/workflow systems for 2D/3D mammography, isotope-free cancer treatment platform technology, and more.

iCAD: Cancer Detection And Therapy Solutions Company Offers Stable Upside

Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

iCAD, Inc. (ICAD) CEO Michael Klein on Q1 2021 Results - Earnings Call Transcript

First Quarter Revenues of $8.6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue

iCAD Reports Financial Results for First Quarter Ended March 31, 2021

NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28.

iCAD to Report First Quarter 2021 Financial Results on Wednesday, April 28

Company expects preliminary estimated revenues to exceed $8.1 million

iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

The FDA has approved iCAD Inc's (NASDAQ: ICAD) ProFound AI Version 3.0 for Digital Breast Tomosynthesis (also known as “3D” mammography used to improve the ability to detect early breast cancers). Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance and a 1% improvement in sensitivity.

iCAD Shares On The Rise After FDA Approval For Third Version Of ProFound AI For 3D Mammography

The stock price of iCAD Inc (NASDAQ: ICAD) has increased by over 15% pre-market. This is why it happened.

ICAD Stock Price Increases Over 15% Pre-Market: Why It Happened

Company's third generation AI solution offers significant improvement in algorithm specificity performance and faster processing compared to previous versions of the software

iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography

Company showcased expanded ProFound AI platform, including ProFound AI Risk, the world's first clinical decision support tool that provides a highly accurate short-term risk estimation specific to each woman

New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting

Icad (ICAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Icad (ICAD) Soars 8.5%: Is Further Upside Left in the Stock?

NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD's Chairman and Chief Executive Officer, will deliver a formal presentation at the Cowen 41st Annual Health Care Conference on Thursday, March 4th at 12:10pm ET and will also conduct one-on-one meetings with investors.

iCAD to Participate in the Cowen 41st Annual Health Care Conference

NASHUA, N.H., March 03, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the pricing of an underwritten public offering of 1,222,222 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds of the offering to the Company are expected to be approximately $22.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, the Company granted the underwriters a thirty-day option to purchase up to an additional 171,516 shares of common stock at the public offering price, less underwriting discounts and commissions.

iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock

NASHUA, N.H., March 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

iCAD Announces Proposed Public Offering of Common Stock

iCAD (ICAD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

iCAD (ICAD) in Focus: Stock Moves 7.6% Higher

iCAD's (ICAD) CEO Michael Klein on Q4 2020 Results - Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of 25.00% and 30.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q4 Loss, Tops Revenue Estimates

Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI® Product Revenue

iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020

NASHUA, N.H., Feb. 18, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, February 24.

iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24

Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Icad (ICAD) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

NASHUA, N.H., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD's Chairman and Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18th at 4:30pm ET and will also conduct one-on-one meetings with investors.

iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

As of late, it has definitely been a great time to be an investor in iCAD, Inc. (ICAD).

News for iCAD Stock (ICAD)